Engineering For New Heights in the Treatment of Inflammatory Bowel Disease
Location: United States, Massachusetts, Waltham
Investors 1
| Date | Name | Website |
| 24.02.2024 | Aisling Ca... | aislingcap... |
Mentions in press and media 6
| Date | Title | Description |
| 10.09.2024 | Spyre Therapeutics to Participate in Upcoming Investor Conference | WALTHAM, Mass., Sept. 10, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approache... |
| 18.06.2024 | Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease | Preclinical data for SPY001 demonstrate the potential for improved dosing over standard of care, including the potential for dosing every eight or twelve weeks compared to dosing every two weeks for subcutaneous vedolizumab Interim subcutan... |
| 03.06.2024 | Spyre Therapeutics Announces Grants of Inducement Awards | WALTHAM, Mass., June 3, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeuti... |
| 29.05.2024 | Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference | WALTHAM, Mass., May 29, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeuti... |
| 03.05.2024 | Spyre Therapeutics Announces Grants of Inducement Awards | WALTHAM, Mass., May 3, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic... |
| 01.04.2024 | Spyre Therapeutics Announces Grants of Inducement Awards | WALTHAM, Mass., April 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeut... |